HK1231513A1 - 活化素抑制劑應答預測和用於治療的用途 - Google Patents

活化素抑制劑應答預測和用於治療的用途

Info

Publication number
HK1231513A1
HK1231513A1 HK17105069.6A HK17105069A HK1231513A1 HK 1231513 A1 HK1231513 A1 HK 1231513A1 HK 17105069 A HK17105069 A HK 17105069A HK 1231513 A1 HK1231513 A1 HK 1231513A1
Authority
HK
Hong Kong
Prior art keywords
treatment
response prediction
inhibitor response
activin inhibitor
activin
Prior art date
Application number
HK17105069.6A
Other languages
English (en)
Inventor
Christopher Michael Haqq
Original Assignee
Santa Maria Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Maria Biotherapeutics Inc filed Critical Santa Maria Biotherapeutics Inc
Publication of HK1231513A1 publication Critical patent/HK1231513A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK17105069.6A 2014-01-14 2017-05-19 活化素抑制劑應答預測和用於治療的用途 HK1231513A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927413P 2014-01-14 2014-01-14
US201462022842P 2014-07-10 2014-07-10
PCT/US2015/011396 WO2015108972A1 (en) 2014-01-14 2015-01-14 Activin inhibitor response prediction and uses for treatment

Publications (1)

Publication Number Publication Date
HK1231513A1 true HK1231513A1 (zh) 2017-12-22

Family

ID=53543394

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105069.6A HK1231513A1 (zh) 2014-01-14 2017-05-19 活化素抑制劑應答預測和用於治療的用途

Country Status (4)

Country Link
US (1) US20160333418A1 (zh)
EP (1) EP3094751A4 (zh)
HK (1) HK1231513A1 (zh)
WO (1) WO2015108972A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20150115961A (ko) 2005-11-23 2015-10-14 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
PT2120999E (pt) 2007-02-09 2012-12-10 Acceleron Pharma Inc Antagonista de activina-actriia e usos para promover o crescimento ósseo em doentes de cancro
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK2340031T3 (da) 2008-08-14 2019-07-15 Acceleron Pharma Inc Gdf-fanger til anvendelse ved behandling af anæmi
EP3805259A1 (en) 2009-06-12 2021-04-14 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
WO2018089706A2 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CA3043489A1 (en) 2016-11-21 2018-05-24 Nanostring Technologies, Inc. Chemical compositions and methods of using same
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
CN112292144A (zh) 2018-01-12 2021-01-29 科乐斯疗法公司 激活素受体iib型变体及其使用方法
EP3794146A1 (en) 2018-05-14 2021-03-24 Nanostring Technologies, Inc. Chemical compositions and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1237565B1 (en) * 1999-12-15 2006-03-08 Research Development Foundation Betaglycan as an inhibin receptor and uses thereof
US20050266519A1 (en) * 2001-12-12 2005-12-01 Prostate Diagnostics Pty. Ltd. (Pdpl) Methods and compositions for modulating and detecting activin dimer and dimer formation
JP2008507288A (ja) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
CR20160443A (es) * 2008-11-26 2016-11-08 Amgen Inc Variantes de polipéptidos receptores de activina iib y aplicaciones de éstos (divisional)
NZ595235A (en) * 2009-04-27 2013-06-28 Novartis Ag Compositions and methods for increasing muscle growth
ES2361808B8 (es) * 2009-05-25 2012-11-29 Consejo Superior De Investigaciones Cientificas (Csic) 20% Método de obtención de datos útiles para el diagnóstico o el pronóstico del cáncer colorrectal.

Also Published As

Publication number Publication date
EP3094751A1 (en) 2016-11-23
EP3094751A4 (en) 2017-06-07
WO2015108972A1 (en) 2015-07-23
US20160333418A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
HK1231513A1 (zh) 活化素抑制劑應答預測和用於治療的用途
IL287113A (en) smyd inhibitors
FI3215147T3 (fi) Hermostoa salpaavia norketamiiniyhdisteitä ja -menetelmiä
SG11201606577YA (en) TARGETED TGFβ INHIBITION
AP2016009371A0 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
GB201403536D0 (en) Inhibitor compounds
IL265139B (en) Dopamine-b-hydroxylase inhibitors
SI3164394T1 (sl) GLS1 inhibitorji za zdravljenje bolezni
HRP20181265T1 (hr) Mif inhibitori
GB201612860D0 (en) Inhibitors
HK1243342A1 (zh) 化合物和方法
GB201501004D0 (en) Inhibitors
GB201412011D0 (en) Treatments
HK1250926A1 (zh) 抑制劑及其應用
GB201401005D0 (en) Inhibitor
GB201411027D0 (en) Treatment
GB201400311D0 (en) Treating Susceptibility
GB201520949D0 (en) Inhibitors
GB201505971D0 (en) Inhibitors and their uses
GB201505975D0 (en) Inhibitors and their uses
GB201418154D0 (en) Inhibitors
GB201415876D0 (en) Methods for the treatment and prevention of Ebola
GB201413317D0 (en) Atheroscierosis treatment